[HTML][HTML] Decreased injection site pain associated with phosphate-free etanercept formulation in rheumatoid arthritis or psoriatic arthritis patients: a randomized …
S Cohen, A Samad, E Karis, BS Stolshek… - Rheumatology and …, 2019 - Springer
Introduction Etanercept, a tumor necrosis factor inhibitor, is used to treat rheumatoid arthritis
(RA) and psoriatic arthritis (PsA), and is administered via subcutaneous injection. Injection …
(RA) and psoriatic arthritis (PsA), and is administered via subcutaneous injection. Injection …
Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA)
PJ Mease, DD Gladman, AS Samad, LC Coates… - RMD open, 2018 - rmdopen.bmj.com
Objective To evaluate the efficacy of etanercept and methotrexate as monotherapies and as
combination therapy in subjects with active psoriatic arthritis (PsA). Methods The Study of …
combination therapy in subjects with active psoriatic arthritis (PsA). Methods The Study of …
Pharmacokinetics, immunogenicity, and efficacy of etanercept in pediatric patients with moderate to severe plaque psoriasis
RG Langley, S Kasichayanula, M Trivedi… - The Journal of …, 2018 - Wiley Online Library
Etanercept has been recently approved in the United States for the treatment of moderate to
severe plaque psoriasis in patients aged 4–17 years. The objective of this study was to …
severe plaque psoriasis in patients aged 4–17 years. The objective of this study was to …
[HTML][HTML] Defining and characterizing sustained remission in patients with rheumatoid arthritis
The objective of this study is to characterize stability and clinical features of patients with
rheumatoid arthritis (RA) in sustained remission. Combination therapy with methotrexate …
rheumatoid arthritis (RA) in sustained remission. Combination therapy with methotrexate …
[HTML][HTML] Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic …
PJ Mease, NA Accortt, S Rebello, CJ Etzel… - Rheumatology …, 2019 - Springer
This study described treatment patterns in a psoriatic arthritis (PsA) patient registry for new
or ongoing tumor necrosis factor inhibitor (TNFi) monotherapy, conventional synthetic …
or ongoing tumor necrosis factor inhibitor (TNFi) monotherapy, conventional synthetic …
Open-Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast.
J Bagel, AS Samad, BS Stolshek, GA Aras… - Journal of Drugs in …, 2018 - europepmc.org
Methods In this multicenter, open-label, single-arm, phase 4, estimation study, subjects with
moderate to severe plaque psoriasis received etanercept 50 mg SC twice weekly for 12 …
moderate to severe plaque psoriasis received etanercept 50 mg SC twice weekly for 12 …
[CITATION][C] Annals of the Institute of Statistical Mathematics acknowledges the following in-dividuals who served as referees from April 1993 to March 1994.
M Akahira, H Akaike, S Aki, MG Akritas, S Amari… - Springer
Annals of the Institute of Statistical Mathematics acknowledges the following in- Page 1
Acknowledgement Annals of the Institute of Statistical Mathematics acknowledges the following …
Acknowledgement Annals of the Institute of Statistical Mathematics acknowledges the following …